Stifel lowered the firm’s price target on MEI Pharma to $7 from $8 and keeps a Hold rating on the shares. Preliminary Phase 1 voruciclib/venetoclax dose-escalation data in relapsed/refractory AML patients is now expected in Q1, notes the firm, which expects a “catalyst-rich” first half of 2024 to improve visibility into the earlier-stage pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MEIP:
